Spectrum Pharmaceuticals

Spectrum Pharmaceuticals is an American biotechnology company that specializes in the development and commercialization of oncology and hematology drugs. The company was founded in 1987 and is headquartered in Henderson, Nevada.

History[edit]

Spectrum Pharmaceuticals was established in 1987. Over the years, the company has developed a diverse portfolio of drug candidates with a focus on oncology and hematology. Spectrum's strategy includes acquiring or in-licensing clinical-stage drug candidates and completing the required clinical testing and regulatory filings to obtain approval from the FDA.

Products[edit]

Spectrum Pharmaceuticals' product portfolio includes several FDA-approved drugs such as Fusilev, Zevalin, and Marqibo. These drugs are used for the treatment of various types of cancers including colorectal cancer, non-Hodgkin's lymphoma, and acute lymphoblastic leukemia.

Fusilev[edit]

Fusilev (levoleucovorin) is used for the treatment of metastatic colorectal cancer. It is also used to reduce the harmful effects of methotrexate, a medication used for the treatment of certain types of cancer.

Zevalin[edit]

Zevalin (ibritumomab tiuxetan) is used for the treatment of patients with relapsed or refractory, low-grade or follicular B-cell non-Hodgkin's lymphoma.

Marqibo[edit]

Marqibo (vinCRIStine sulfate LIPOSOME injection) is used for the treatment of adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia.

Research and Development[edit]

Spectrum Pharmaceuticals is actively involved in the research and development of new drug candidates. The company's pipeline includes several drugs in various stages of clinical development aimed at treating different types of cancers.